Clinical Trials
71 trialsPhase I Trial of MT-0169 in CD38+ Acute Leukemia With Relapsed/Refractory or Measurable Residual Disease
M.D. Anderson Cancer Center
Immune Reconstitution Monitoring and Pneumococcal Vaccination in Patients Treated With CAR-T Cells
UNC Lineberger Comprehensive Cancer Center
Physical Activity and Quality of Life in Childhood Cancersurvivors- a Long-term Follow-up
Region Skane
Optimized Dual CD33/CLL1 CAR T Cells in Subjects With Refractory or Relapsed Acute Myeloid Leukemia
Beijing Boren Hospital
A Phase I Trial of Donor- Derived 19-28z CAR T Cells Following Allogeneic Transplant for the Treatment of CD19 Malignancies
Memorial Sloan Kettering Cancer Center
Safety and Efficacy Study of CI-135 CAR-T Cells in Subjects with Relapsed or Refractory Acute Myeloid Leukemia
Beijing Boren Hospital
Donor-Derived CD5 CAR T (CT125B) Cells for Relapsed or Refractory T- Cell Acute Lymphoblastic Leukemia/Lymphoma
Beijing Boren Hospital
Collection of Blood and/or Bone Marrow for Investigation and Characterization of Normal and Abnormal Cell Growth
University of Massachusetts, Worcester
Donor Enriched Activated NK Cell Infusion Post Haploidentical Stem Cell Transplant for Refractory Myeloid Malignancies
University of Nebraska
A Study of Fedratinib With IDH Inhibition in Advanced-Phase, IDH-Mutated Ph-Negative Myeloproliferative Neoplasms
University of Chicago
HEM-iSMART A
Princess Maxima Center for Pediatric Oncology
Safety Trial of STING-dependent Activators and Stimulated Dendritic Cells for Aggressive Relapsed/Refractory Leukemias
University of Miami
Donor Stem Cell Transplant, Pentostatin, and Total-Body Irradiation in Treating Patients With Hematological Cancer
University of Nebraska
H-9926-LCH III: Treatment Protocol of the Third International Study for Langerhans Cell Histiocytosis
University of New Mexico
SABRE
Imperial College Healthcare NHS Trust
Companion for CAR-T Web App During Chimeric Antigen Receptor T-cell Therapy
University of California, San Francisco
Amifostine & High-Dose Combination Chemotherapy in Treating Patients With Acute ML or CML
Rush University Medical Center
STP-LYM-01
Technical University of Munich
Acalabrutinib for GVHD Prophylaxis in Allogeneic Hematopoietic Stem Cell Transplantation in Lymphomas and Leukemia
Milton S. Hershey Medical Center
Combination Chemotherapy Plus Biological Therapy in Treating Patients With Acute Myelogenous Leukemia
Rush University Medical Center
Collecting and Storing Blood Samples From Patients With Cancer
Rutgers, The State University of New Jersey
Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Advanced Hematologic Cancer
Jonsson Comprehensive Cancer Center
Donor Lymphocytes to Prevent Graft-Versus-Host Disease in Patients With Chronic Myeloid Leukemia
Jonsson Comprehensive Cancer Center
Infusion of Allogeneic, 3rd Party CD19-specific T Cells
M.D. Anderson Cancer Center
Bone Marrow Transplantation in Treating Patients With Leukemia
Masonic Cancer Center, University of Minnesota
Alemtuzumab Plus Fludarabine and Melphalan With or Without Cyclosporine, Mycophenolate Mofetil, and Low-Dose Total-Body Irradiation Therapy Followed by Donor Peripheral Stem Cell Transplant in Treating Patients With Hematologic Cancer
Alliance for Clinical Trials in Oncology
Haplo-identical SCT for High Risk (HR) Hematologic Malignancies w/Post-Transplant In-Vivo T-cell Depletion
Ann & Robert H Lurie Children's Hospital of Chicago
A Study Using Two Oral Chemotherapy Agents for Chronic Lymphocytic Leukemia
Scripps Health
Arsenic Trioxide in Treating Patients With Chronic Phase Chronic Myelogenous Leukemia That Has Not Responded to Previous Treatment
M.D. Anderson Cancer Center
Patient-Driven Transfusion Thresholds in Hematological Disorders: A Pilot Study
Emory University
Phase II Study of VELCADE for Relapsed or Refractory T-cell Prolymphocytic Leukemia
Stanford University
Volasertib Combined With Induction Chemotherapy in Acute Myeloid Leukemia
Massachusetts General Hospital
Pre and Post Treatment Metabolomic Analysis of Leukemia: A Translational Clinical Trial of the Brown Cancer Center
University of Louisville
Autologous ROR1R-CAR-T Cells for Chronic Lymphocytic Leukemia (CLL)
M.D. Anderson Cancer Center
Dose-Escalation Study of Ponatinib, a FLT3 Inhibitor, With and Without Combination of 5-Azacytidine, in Patients With FLT3-Mutated Acute Myeloid Leukemia (AML)
M.D. Anderson Cancer Center
DETECS
University of Colorado, Denver
Urelumab (CD137 mAb) With Rituximab for Relapsed, Refractory or High-risk Untreated Chronic Lymphocytic Leukemia (CLL) Patients
M.D. Anderson Cancer Center
Randomized Trial of Mobilized Blood/Marrow Versus Blood Transplant
Peking University People's Hospital
Immunotherapy for Lymphoproliferative Diseases Associated With Epstein-Barr Virus in Patients Who Have Undergone Organ Transplants
University of Alabama at Birmingham
A Novel Magnetic Needle Using Iron Oxide Nanoparticles for the Detection of Leukemia
University of New Mexico
Dietary and Exercise Interventions in Preventing Cardiovascular Disease in Younger Survivors of Leukemia, Lymphoma, or Brain Tumors
Virginia Commonwealth University
Autologous Stem Cell Transplants for Chronic Myelogenous Leukemia
M.D. Anderson Cancer Center
Monoclonal Antibody Therapy or Biological Therapy in Treating Patients With Chronic Lymphocytic Leukemia or Multiple Myeloma in Remission After Chemotherapy
Hoag Memorial Hospital Presbyterian
Autologous Cytomegalovirus (CMV) Specific CD8+ T Cells as Treatment for CMV Reactivation
Imperial College London
CD56+CD3- NK Cells Following Allogeneic Stem Cell Transplantation
Imperial College London
Perceptions of Burden in Patients With Late-Stage Cancer and Their Caregivers
Rutgers, The State University of New Jersey
The Role of Maintenance Oral Clofarabine in Older Adults With Acute Myeloid Leukemia
Northwestern University
Acupuncture for Mucositis Pain in Cancer Care
Johns Hopkins University
Prevention of Graft-Versus-Host Disease in Patients With Hematologic Malignancies Who Are Receiving a Bone Marrow Transplant
Fred Hutchinson Cancer Center
Lenalidomide With or Without Rituximab in Treating Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Who Have Undergone Autologous or Syngeneic Stem Cell Transplant
Fred Hutchinson Cancer Center